The Northridge, California–based diabetes tech company, spun out of Medtronic earlier this year, announced a CE mark for its next-gen, app-controlled MiniMed Flex insulin pump — well ahead of the company’s calendar 2026 year-end target. MiniMed officials expect a European commercial launch in November. The automated system already launched in the U.S. over the summer after FDA clearance in March.
“This is a proud moment for our team and an important step forward for people living with diabetes across Europe,” MiniMed CEO Que Dallara said in a news release. “We believe diabetes technology should deliver best-in-class clinical outcomes while being discreet enough to fade into everyday life. This milestone brings us closer to making that experience available to more people across Europe.”
The news, along with a positive Q1 report, sent MMED shares up more than 11% to $22.56 apiece by midday trading today. The S&P 500 was down slightly.
